SARS-CoV-2 (Spike Protein) Delta/B.1.617.2 WT Reference Peptide Pool



Scientists Helping Scientists™ | www.stemcell.com

SARS-CoV-2 (spike protein) Delta/B.1.617.2 variant wild-type reference peptide pool for immune cell activation

Catalog #100-1381 ~25 μg (15 nmol)/peptide

TOLL FREE PHONE 1 800 667 0322 • PHONE +1 604 877 0713 INFO@STEMCELL.COM • TECHSUPPORT@STEMCELL.COM FOR GLOBAL CONTACT DETAILS VISIT OUR WEBSITE

Product Description

SARS-CoV-2 (Spike Protein) Delta/B.1.617.2 WT Reference Peptide Pool is a lyophilized mixture of 27 peptides from the spike glycoprotein of SARS-CoV-2 wild-type. The pool represents the wild-type peptides of the mutations in the spike protein of SARS-CoV-2 Delta variant (B.1.617.2) and is recommended as a reference. The virus attaches to the cell membrane of the host through the interaction between spike protein and angiotensin-converting enzyme 2 (ACE2) receptor, and the spike protein plays a critical role in viral entry (Hoffmann et al.; Walls et al.). One unit of this product (i.e. \sim 25 µg/peptide) is sufficient for stimulating 2.5 x 10^8 cells.

APPLICATIONS

- Antigen-specific T cell stimulation
- Cellular immune response
- Immune monitoring
- T cell assays
- T cell expansion

Product Information

Number of Peptides: 27

Source: SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), wild-type

Accession Number: P0DTC2

Protein Name: S glycoprotein; Spike glycoprotein; Surface glycoprotein

Gene Name:

Purity: Average 70%

Formulation: Lyophilized as trifluoroacetate salts

Preparation and Storage

Storage: Store at -20°C.

Stability: Stable as supplied until expiry date (EXP) on label.

Preparation: Warm to room temperature (15 - 25°C) before reconstitution. Add pure dimethyl sulfoxide (DMSO; ~40 µL) and

dilute with water to the desired concentration. Final concentration of DMSO must be below 1% (v/v) to avoid toxicity in the biological system. If not used immediately, aliquot and store at -20°C. Protect from light. Avoid

repeated freeze-thaw cycles.



Peptide Sequences

NO.	SEQUENCE	LENGTH
1	LVLLPLVSSQCVNLT	15
2	PLVSSQCVNLTTRTQ	15
3	SQCVNLTTRTQLPPA	15
4	NLTTRTQLPPAYTNS	15
5	YHKNNKSWMESEFRV	15
6	NKSWMESEFRVYSSA	15
7	MESEFRVYSSANNCT	15
8	FRVYSSANNCTFEYV	15
9	LDSKVGGNYNYLYRL	15
10	VGGNYNYLYRLFRKS	15
11	YNYLYRLFRKSNLKP	15
12	ERDISTEIYQAGSTP	15
13	STEIYQAGSTPCNGV	15
14	YQAGSTPCNGVEGFN	15

NO.	SEQUENCE	LENGTH
15	STPCNGVEGFNCYFP	15
16	GTNTSNQVAVLYQDV	15
17	SNQVAVLYQDVNCTE	15
18	AVLYQDVNCTEVPVA	15
19	QDVNCTEVPVAIHAD	15
20	GICASYQTQTNSPRR	15
21	SYQTQTNSPRRARSV	15
22	QTNSPRRARSVASQS	15
23	PRRARSVASQSIIAY	15
24	SLSSTASALGKLQDV	15
25	TASALGKLQDWNQN	15
26	LGKLQDVVNQNAQAL	15
27	QDVVNQNAQALNTLV	15

Related Products

For a complete list of peptide pools, as well as related products available from STEMCELL Technologies, visit www.stemcell.com, or contact us at techsupport@stemcell.com.

References

Hoffmann M et al. (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181(2): 271–80.

Walls AC et al. (2020) Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181(2): 281–92.

PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED.

Copyright © 2023 by STEMCELL Technologies Inc. All rights reserved including graphics and images. STEMCELL Technologies & Design, STEMCELL Shield Design, and Scientists Helping Scientists are trademarks of STEMCELL Technologies Canada Inc. All other trademarks are the property of their respective holders. While STEMCELL has made all reasonable efforts to ensure that the information provided by STEMCELL and its suppliers is correct, it makes no warranties or representations as to the accuracy or completeness of such information.